Champions Oncology (NASDAQ:CSBR) Posts Earnings Results, Beats Expectations By $0.06 EPS

Champions Oncology (NASDAQ:CSBR) released its quarterly earnings results on Monday. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.06, FiscalAI reports. Champions Oncology had a negative net margin of 3.94% and a negative return on equity of 57.31%. The firm had revenue of $13.84 million for the quarter, compared to analyst estimates of $12.89 million.

Here are the key takeaways from Champions Oncology’s conference call:

• Champions Oncology reported record fiscal 2026 revenue of $59.4 million, up 12%, driven by 12% growth in Study Services to $58.7 million.
• The company achieved its goal of positive adjusted EBITDA, posting $1.6 million for the year and positive adjusted EBITDA in all four quarters for the first time since fiscal 2022.
• Gross margin improved to 51% in the fourth quarter as the company reduced outsourced radiopharmaceutical costs by bringing more work in-house, a shift management expects to support further margin gains.
• Data-license revenue fell to approximately $800,000 from $4.7 million because a large prior-year transaction did not recur, although some expected revenue shifted into fiscal 2027 and the customer pipeline expanded.
• Management remains encouraged by Corellia’s therapeutic data and is pursuing venture funding or a pharmaceutical licensing partnership; however, no specific timing was provided, and the company plans to fund the subsidiary internally for fiscal 2027 if necessary.

Champions Oncology Stock Down 0.8%

NASDAQ:CSBR opened at $6.08 on Tuesday. Champions Oncology has a 52 week low of $5.50 and a 52 week high of $8.74. The stock’s fifty day moving average is $6.06 and its two-hundred day moving average is $6.18. The stock has a market capitalization of $84.45 million, a price-to-earnings ratio of -38.00 and a beta of 0.39.

Institutional Investors Weigh In On Champions Oncology

Several institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. purchased a new position in Champions Oncology during the 1st quarter valued at about $201,000. Jane Street Group LLC purchased a new stake in Champions Oncology during the first quarter worth about $200,000. Acadian Asset Management LLC increased its stake in Champions Oncology by 28.7% during the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 8,814 shares during the period. XTX Topco Ltd acquired a new stake in shares of Champions Oncology during the second quarter worth about $103,000. Finally, Vanguard Group Inc. lifted its position in shares of Champions Oncology by 1.9% during the third quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock worth $2,158,000 after purchasing an additional 6,229 shares in the last quarter. Hedge funds and other institutional investors own 41.30% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Champions Oncology currently has a consensus rating of “Sell”.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.